Following neoadjuvant therapy, 55.7% of patients ( n = 39/70) had pT3 disease, 40% ( n = 28) had seminal vesicle invasion, 12.9% ( n = 9) had positive margins, and 11.4% ( n = 8) had lymph node involvement. Overall, 72 patients were included of whom the majority had a Gleason score ≥ 8 ( n = 46, 63.9%). BCR was defined as a PSA ≥ 0.2 ng/mL or treatment with radiation or androgen-deprivation therapy for a rising PSA < 0.2 ng/mL. The primary endpoint was time to biochemical recurrence (BCR). All patients received intense ADT prior to RP. We conducted a pooled analysis of patients with available follow-up data treated on three neoadjuvant trials at three institutions. In this analysis, we report on the post-RP outcomes of a subset of patients enrolled on these studies. We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |